Zai Lab Joins Latest Oncology Race With Mirati KRAS Deal

 
• By Dexter Jie Yan

Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.

competition
ZAI LAB JOINS KRAS RACE IN CHINA WITH MIRATI DEAL • Source: Alamy

More from China

More from Focus On Asia